-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Timber Pharmaceuticals (NYSE:TMBR) Shares Down 6%
Timber Pharmaceuticals (NYSE:TMBR) Shares Down 6%
Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating)'s share price fell 6% during mid-day trading on Monday . The stock traded as low as $0.11 and last traded at $0.11. 4,525,740 shares traded hands during mid-day trading, a decline of 19% from the average session volume of 5,556,676 shares. The stock had previously closed at $0.12.
Analyst Upgrades and Downgrades
Separately, HC Wainwright lowered their price objective on Timber Pharmaceuticals from $1.50 to $1.00 and set a "buy" rating on the stock in a report on Monday, August 29th.
Get Timber Pharmaceuticals alerts:Timber Pharmaceuticals Price Performance
The stock has a fifty day moving average of $0.16 and a two-hundred day moving average of $0.25. The stock has a market capitalization of $14.57 million, a price-to-earnings ratio of -0.33 and a beta of 0.27. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 1.30.
Timber Pharmaceuticals (NYSE:TMBR – Get Rating) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.05). Timber Pharmaceuticals had a negative return on equity of 228.75% and a negative net margin of 1,274.17%. As a group, equities research analysts forecast that Timber Pharmaceuticals, Inc. will post -0.17 earnings per share for the current year.Institutional Trading of Timber Pharmaceuticals
An institutional investor recently raised its position in Timber Pharmaceuticals stock. Renaissance Technologies LLC boosted its holdings in shares of Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating) by 37.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 871,237 shares of the company's stock after buying an additional 238,663 shares during the quarter. Renaissance Technologies LLC owned approximately 1.36% of Timber Pharmaceuticals worth $335,000 at the end of the most recent reporting period. 5.78% of the stock is currently owned by institutional investors and hedge funds.
Timber Pharmaceuticals Company Profile
(Get Rating)
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs.
Featured Articles
- Get a free copy of the StockNews.com research report on Timber Pharmaceuticals (TMBR)
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
Receive News & Ratings for Timber Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Timber Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating)'s share price fell 6% during mid-day trading on Monday . The stock traded as low as $0.11 and last traded at $0.11. 4,525,740 shares traded hands during mid-day trading, a decline of 19% from the average session volume of 5,556,676 shares. The stock had previously closed at $0.12.
周一午盘，Wood PharmPharmticals Inc.(纽约证券交易所代码：TMBR-GET Rating)股价下跌6%。该股盘中一度跌至0.11美元，最新报0.11美元。午盘交易中，有4,525,740股股票易手，较5,556,676股的平均成交量下降19%。该股此前收盘报0.12美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Separately, HC Wainwright lowered their price objective on Timber Pharmaceuticals from $1.50 to $1.00 and set a "buy" rating on the stock in a report on Monday, August 29th.
另外，HC Wainwright在8月29日(星期一)的一份报告中将Timber PharmPharmticals的目标价从1.50美元下调至1.00美元，并对该股设定了“买入”评级。
Timber Pharmaceuticals Price Performance
木材药品价格表现
The stock has a fifty day moving average of $0.16 and a two-hundred day moving average of $0.25. The stock has a market capitalization of $14.57 million, a price-to-earnings ratio of -0.33 and a beta of 0.27. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 1.30.
该股的50日移动均线为0.16美元，200日移动均线为0.25美元。该股市值为1,457万美元，市盈率为-0.33，贝塔系数为0.27。该公司的流动比率为1.41，速动比率为1.41，债务权益比率为1.30。
Institutional Trading of Timber Pharmaceuticals
木材药品的制度性交易
An institutional investor recently raised its position in Timber Pharmaceuticals stock. Renaissance Technologies LLC boosted its holdings in shares of Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating) by 37.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 871,237 shares of the company's stock after buying an additional 238,663 shares during the quarter. Renaissance Technologies LLC owned approximately 1.36% of Timber Pharmaceuticals worth $335,000 at the end of the most recent reporting period. 5.78% of the stock is currently owned by institutional investors and hedge funds.
一家机构投资者最近提高了对Timber PharmPharmticals股票的头寸。复兴科技有限责任公司在提交给美国证券交易委员会的最新Form 13F文件中称，该公司第一季度增持了37.7%的Timber PharmPharmticals，Inc.股票。该基金在本季度额外购买了238,663股后，持有该公司871,237股股票。在最近一次报告期结束时，复兴技术公司拥有木材制药公司约1.36%的股份，价值33.5万美元。5.78%的股票目前由机构投资者和对冲基金持有。
Timber Pharmaceuticals Company Profile
木材制药公司简介
(Get Rating)
(获取评级)
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs.
Wood PharmPharmticals LLC是一家临床阶段的生物制药公司，致力于孤儿皮肤病治疗药物的开发和商业化。该公司的主要候选产品包括TMB-001和TMB-002，TMB-001是异维A酸的专利局部制剂，已完成2b阶段临床试验，用于治疗中到重度CI，这是一组罕见的遗传性角化性疾病；以及TMB-002，是雷帕霉素的专利局部制剂，用于治疗结节性硬化症中的面部血管纤维瘤，这是一种导致多器官错构瘤生长的多系统遗传疾病。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Timber Pharmaceuticals (TMBR)
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- 免费获取StockNews.com关于木材制药的研究报告(TMBR)
- Lucid看起来像是电动汽车的赢家
- 仍然爱着它：投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗？
- 自动区重新进入拉力赛模式，新高在望
- Upwork股价跌入便宜货领域
Receive News & Ratings for Timber Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Timber Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受《木材医药日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对木材制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧